ACHE and Alzheimer disease: Despite this uncertainty, one strategy in designing AChE inhibitors for use in against Alzheimer’s disease, has been to incorporate binding both at the catalytic site (to spare acetylcholine) and at the peripheral site (to prevent facilitation of Aβ aggregation).